


Pro-Stride® APS is a comprehensive orthobiologic device for managing equine osteoarthritis (OA).

What's in Pro-Stride® APS?




All three components (Plasma, Platelets and WBC) are optimal for comprehensive OA management.^{1,2}

Comprehensive Orthobiologic Device for a Complex Disease

OA is a complex process that ultimately breaks down cartilage. Inflammatory proteins like IL-1, TNF-α, MMP-13 and aggrecanase need to be neutralized to prevent joint deterioration.

The Pro-Stride APS device concentrates horses' naturally occurring anti-inflammatory proteins and growth factors to address this complex process.¹

X Pro-Stride inhibits multiple inflammatory pathways and provides growth factors to support healing.



1. Muir et al. The Concentration of Plasma Provides Additional Bioactive Proteins in Platelet and Autologous Protein Solutions. Am J Sports Med. 2019 Jul;47(8):1955-1963.
2. nSTRIDE APS Scientific Narrative, Zimmer Biomet, Internal Document.

Evaluation of plasma protein composition in Restigen® PRP, Pro-Stride® APS and PPP compared to Alpha2EQ® devices³

Study objective

To demonstrate concentrations of Alpha-2-macroglobulin (A2M) and other proteins found following processing with Restigen PRP, Pro-Stride APS and Alpha2EQ devices.


Study methods

13 horses in three geographic locations were utilized (a private practice in Missouri, the University of Pennsylvania New Bolton Center and Colorado State University CVM). Blood samples were obtained and processed by independent veterinarians. Plasma protein analysis was performed by proteomics at Zoetis Veterinary Medical Research and Development in Kalamazoo, MI.


Study results

1. A2M concentration of plasma is equivalent between all three devices.
2. There are significantly higher concentrations of A2M in the final output of Pro-Stride APS and Restigen PRP versus Alpha2EQ.
3. The PPP portion of Pro-Stride APS and Restigen PRP had identical protein profiles as compared to Alpha2EQ.

A2M concentration of plasma compared by device



A2M concentration in final outputs



What does this mean?

In this study, the PPP portion of Restigen PRP and Pro-Stride APS was the same as the final output of Alpha2EQ.

| | A2M | Plasma proteins and soluble anti-inflammatory cytokines (TNF-R1, IGF-1) | Platelet-derived growth factors (PDGR, VEGF and others) | WBC-derived anti-inflammatory cytokines (IL1-ra, IL-10 and others) |
|--|---|---|---|--|
| Pro-Stride APS (3 mL) | 2.7X concentrated over plasma | ✓ | ✓ | ✓ |
| Restigen PRP (6 mL) | 1.8X concentrated over plasma | ✓ | ✓ | ✓ |
| Pro-Stride or Restigen PPP portion from device 1 (30 mL) | Plasma A2M and other protein composition equivalent between devices | ✓ | | |
| Alpha2EQ (30 mL) | Plasma A2M and other protein composition equivalent between devices | No published data | | |

3. Zoetis Inc. Data on file. Study report no. 23EQRGRMD-01-03.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. Stablelab is a registered trademark of Epona Biotech Limited, used under license. Dormosedan is a registered trademark of Orion Corporate; distributed by Zoetis under license.

© 2023 Zoetis Services LLC. All rights reserved. GEQ-01139